U.S. markets close in 5 hours 31 minutes
  • S&P 500

    3,677.81
    +8.80 (+0.24%)
     
  • Dow 30

    30,005.55
    +121.76 (+0.41%)
     
  • Nasdaq

    12,421.50
    +72.13 (+0.58%)
     
  • Russell 2000

    1,846.88
    +8.85 (+0.48%)
     
  • Crude Oil

    45.27
    -0.01 (-0.02%)
     
  • Gold

    1,839.90
    +9.70 (+0.53%)
     
  • Silver

    24.10
    +0.02 (+0.10%)
     
  • EUR/USD

    1.2171
    +0.0056 (+0.46%)
     
  • 10-Yr Bond

    0.9240
    -0.0240 (-2.53%)
     
  • GBP/USD

    1.3485
    +0.0109 (+0.82%)
     
  • USD/JPY

    103.7230
    -0.7010 (-0.67%)
     
  • BTC-USD

    19,401.74
    +452.49 (+2.39%)
     
  • CMC Crypto 200

    381.25
    +6.84 (+1.83%)
     
  • FTSE 100

    6,474.73
    +11.34 (+0.18%)
     
  • Nikkei 225

    26,809.37
    +8.39 (+0.03%)
     

Moving Average Crossover Alert: Intra-Cellular Therapies

Zacks Equity Research

Intra-Cellular Therapies, Inc. ITCI is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for ITCI broke out above the 200 Day Simple Moving Average, suggesting a short-term bullish trend.

This has already started to take place, as the stock has moved higher by more than 100% in the past four weeks. Plus, the company currently has a Zacks Rank #2 (Buy) suggesting that now could definitely be the time for this breakout candidate.

More bullishness may especially be the case when investors consider what has been happening for ITCI on the earnings estimate revision front lately. No estimate has gone lower in the past two months, compared to 5 higher, while the consensus estimate has also moved higher too.

So given this move in estimates, and the positive technical factors, investors may want to watch this breakout candidate closely for more gains in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q3 2019, while the S&P 500 gained +39.6%, five of our strategies returned +51.8%, +57.5%, +96.9%, +119.0%, and even +158.9%.

This outperformance has not just been a recent phenomenon. From 2000 – Q3 2019, while the S&P averaged +5.6% per year, our top strategies averaged up to +54.1% per year.

See their latest picks free >>

 

 

 

 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Intra-Cellular Therapies Inc. (ITCI) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research